(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are OncoSec Medical Incorporated, Mogo, and NantHealth.

The three biggest losers today are Medigus Ltd., Malacca Straits Acquisition Company Limited, and Meten EdtechX Education Group Ltd..

Winners today

1. OncoSec Medical Incorporated (ONCS) – 22.42%

OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was founded in 2008 and is headquartered in Pennington, New Jersey.

NASDAQ ended the session with OncoSec Medical Incorporated jumping 22.42% to $2.73 on Friday, following the last session’s upward trend. NASDAQ rose 0.31% to $11,823.96, after four consecutive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, OncoSec Medical Incorporated has a trailing twelve months EPS of $-13.63.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -410.17%.

More news about OncoSec Medical Incorporated.

2. Mogo (MOGO) – 17.44%

Mogo Inc. operates as a financial technology company in Canada. The company provides finance app that empowers consumers with solutions to help them get in control of their financial wellness. It offers users a Mogo app and provides access to MogoSpend, a digital spending account with Platinum Prepaid Visa Card (MogoCard); MogoCrypto that enables the buying and selling of bitcoin; free monthly credit score monitoring; MogoProtect, a free ID fraud protection; MogoMortgage, a digital mortgage experience; MogoMoney that provides access to personal loans; and bitcoin rewards program to buy bitcoin through MogoCrypto. The company also operates a digital payments platform. Mogo Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

NASDAQ ended the session with Mogo rising 17.44% to $0.66 on Friday while NASDAQ rose 0.31% to $11,823.96.

Earnings Per Share

As for profitability, Mogo has a trailing twelve months EPS of $-1.32.

More news about Mogo.

3. NantHealth (NH) – 11.43%

NantHealth, Inc., together with its subsidiaries, operates as a healthcare IT company in the United States and internationally. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions. The company also provides NaviNet, a suite of SaaS-based solution enabling payers and providers to streamline communication and consolidate information; NaviNet Open, a payer-provider collaboration platform for communication between health plans and providers; NaviNet AllPayer that provides eligibility, benefit, and claim status information to provider offices for commercial and government plans and CMS for Medicare beneficiaries through the NaviNet portal; and OpenNMS is an open-source network monitoring solution for enterprise-grade networks. In addition, it offers GPS Cancer, a comprehensive molecular profile that integrates whole genome/exome (DNA) sequencing of tumor and normal germline samples and whole transcriptome (RNA) sequencing; Omics Core, an in-vitro diagnostic built on a custom-targeted whole exome sequencing platform; and Quadris, a data solution that includes multi-data analysis, reporting, and professional service. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016. The company was incorporated in 2010 and is headquartered in Culver City, California. NantHealth, Inc. is as a subsidiary of NantWorks, LLC.

NASDAQ ended the session with NantHealth jumping 11.43% to $2.34 on Friday, after four consecutive sessions in a row of gains. NASDAQ rose 0.31% to $11,823.96, after four sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, NantHealth has a trailing twelve months EPS of $-0.512.

Revenue Growth

Year-on-year quarterly revenue growth grew by 15.8%, now sitting on 65.53M for the twelve trailing months.

Moving Average

NantHealth’s worth is way under its 50-day moving average of $3.00 and way under its 200-day moving average of $5.13.

More news about NantHealth.

4. Mercurity Fintech Holding (MFH) – 9.9%

Mercurity Fintech Holding Inc. engages in the design, development, creation, testing, installation, configuration, integration, and customization of digital asset infrastructure solutions based on blockchain technologies in the British Virgin Islands and the Asia pacific region. The company provides digital asset trading infrastructure solutions based on internet and blockchain technologies for traders, communities, and liquidity providers; an asset digitalization platform, which provides blockchain-based digitalization solutions for traditional assets that include fiat currencies, bonds, and precious metals. It also offers a decentralized finance platform that solves retail traders' problems; cross-border payments services through NBpay; and supplemental services for its platforms, such as customized software development, maintenance, and compliance support services. The company was formerly known as JMU Limited and changed its name to Mercurity Fintech Holding Inc. in April 2020. Mercurity Fintech Holding Inc. was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Mercurity Fintech Holding rising 9.9% to $1.11 on Friday while NASDAQ jumped 0.31% to $11,823.96.

Earnings Per Share

As for profitability, Mercurity Fintech Holding has a trailing twelve months EPS of $-1.882.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -184.96%.

Yearly Top and Bottom Value

Mercurity Fintech Holding’s stock is valued at $1.11 at 17:32 EST, way under its 52-week high of $2.92 and way higher than its 52-week low of $0.48.

Moving Average

Mercurity Fintech Holding’s worth is way higher than its 50-day moving average of $1.00 and way above its 200-day moving average of $0.88.

Volume

Today’s last reported volume for Mercurity Fintech Holding is 43041 which is 64.71% below its average volume of 121973.

More news about Mercurity Fintech Holding.

5. OptiNose (OPTN) – 9.52%

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase 3b clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.

NASDAQ ended the session with OptiNose jumping 9.52% to $1.84 on Friday while NASDAQ rose 0.31% to $11,823.96.

Earnings Per Share

As for profitability, OptiNose has a trailing twelve months EPS of $-0.84.

Volume

Today’s last reported volume for OptiNose is 92572 which is 40.51% below its average volume of 155621.

More news about OptiNose.

6. Nano Dimension (NNDM) – 8.52%

Nano Dimension Ltd., together with its subsidiaries, provides additive electronics in Israel and internationally. The company's flagship product is DragonFly IV system that serves cross-industry High-Performance-Electronic-Devices' fabrication needs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components. It also provides nanotechnology based conductive and dielectric inks; and FLIGHT software platform that enables the 3D design of electrical and mechanical features. The company markets and sells products and services to companies that develop products with electronic components, including companies in the defense, automotive, consumer electronics, semiconductor, aerospace, and medical industries, as well as research institutes. Nano Dimension Ltd. was founded in 2012 and is headquartered in Ness Ziona, Israel.

NASDAQ ended the session with Nano Dimension jumping 8.52% to $2.60 on Friday, after two consecutive sessions in a row of gains. NASDAQ rose 0.31% to $11,823.96, after four sequential sessions in a row of gains, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Nano Dimension has a trailing twelve months EPS of $-1.129.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.01%.

Moving Average

Nano Dimension’s worth is under its 50-day moving average of $2.70 and under its 200-day moving average of $2.77.

Yearly Top and Bottom Value

Nano Dimension’s stock is valued at $2.60 at 17:32 EST, way below its 52-week high of $3.98 and way above its 52-week low of $2.06.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nano Dimension’s stock is considered to be overbought (>=80).

More news about Nano Dimension.

7. MicroVision (MVIS) – 7.82%

MicroVision, Inc. develops lidar sensors used in automotive safety and autonomous driving applications. Its laser beam scanning technology is based on micro-electrical mechanical systems, laser diodes, opto-mechanics, electronics, algorithms, and software. The company also develops micro-display concepts and designs for head-mounted augmented reality (AR) headsets, as well as 1440i MEMS module that can support AR headsets; Interactive Display modules used in smart speakers and other devices; and Consumer Lidar used in smart home systems. In addition, it provides PicoP, a scanning technology that creates full color, high-contrast, and uniform image over the entire field-of-view from a small and thin module. Further, the company develops 1st generation long range lidar. The company sells its products primarily to original equipment manufacturers and original design manufacturers. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.

NASDAQ ended the session with MicroVision jumping 7.82% to $2.28 on Friday while NASDAQ rose 0.31% to $11,823.96.

Earnings Per Share

As for profitability, MicroVision has a trailing twelve months EPS of $-0.102.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -50.24%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MicroVision’s stock is considered to be overbought (>=80).

Sales Growth

MicroVision’s sales growth is negative 10.2% for the present quarter and 14.3% for the next.

Moving Average

MicroVision’s value is way below its 50-day moving average of $2.57 and way below its 200-day moving average of $3.55.

Volume

Today’s last reported volume for MicroVision is 4781390 which is 125.19% above its average volume of 2123260.

More news about MicroVision.

8. LIZHI (LIZI) – 7.56%

Lizhi Inc. operates an online user-generated content audio community, interactive audio entertainment platform, and online audio platform in China and the United States. It provides podcasts, live streaming, and audio entertainment products. The company also offers Lizhi app that allows users to record and share their voices on mobile devices; Tiya App, an audio-based social networking product; and LIZHI Podcast, a podcast app to provide curated podcast content. The company has collaboration agreements with Xpeng Motors, GAC AION New Energy Automobile, and GAC Motor, as well as with BYD DiLink and Huawei Mobile Services. Lizhi Inc. was incorporated in 2010 and is headquartered in Guangzhou, the People's Republic of China.

NASDAQ ended the session with LIZHI jumping 7.56% to $0.68 on Friday, following the last session’s upward trend. NASDAQ rose 0.31% to $11,823.96, after four consecutive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, LIZHI has a trailing twelve months EPS of $-0.461.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.27%.

Sales Growth

LIZHI’s sales growth is negative 0.4% for the current quarter and negative 7.6% for the next.

Volume

Today’s last reported volume for LIZHI is 198545 which is 57.93% below its average volume of 472005.

Revenue Growth

Year-on-year quarterly revenue growth grew by 12%, now sitting on 2.16B for the twelve trailing months.

Yearly Top and Bottom Value

LIZHI’s stock is valued at $0.68 at 17:32 EST, way below its 52-week high of $1.88 and way above its 52-week low of $0.38.

More news about LIZHI.

9. Afya (AFYA) – 7.43%

Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. The company also provides digital health services, such as subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides medical postgraduate specialization programs; printed and digital content; and an online medical education platform and practical medical training services. As of December 31, 2021, it operated a network of 46 undergraduate and graduate medical school campuses consisted of 30 undergrad operating units and five approved units; and a network of 2,731 medical school seats that consisted of 2,481 operating seats and 278 approved seats. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.

NASDAQ ended the session with Afya jumping 7.43% to $10.70 on Friday, following the last session’s downward trend. NASDAQ jumped 0.31% to $11,823.96, after four successive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Afya has a trailing twelve months EPS of $0.44.

PE Ratio

Afya has a trailing twelve months price to earnings ratio of 24.43. Meaning, the purchaser of the share is investing $24.43 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.9%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 27.8%, now sitting on 2.24B for the twelve trailing months.

Previous days news about Afya

• Afya (afya) misses Q4 earnings and revenue estimates. According to Zacks on Wednesday, 22 March, "While Afya has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"

More news about Afya.

10. Milestone Pharmaceuticals (MIST) – 7.38%

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

NASDAQ ended the session with Milestone Pharmaceuticals rising 7.38% to $3.49 on Friday while NASDAQ jumped 0.31% to $11,823.96.

Earnings Per Share

As for profitability, Milestone Pharmaceuticals has a trailing twelve months EPS of $-1.703.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.71%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is 17.5% and a drop 18.2% for the next.

Volume

Today’s last reported volume for Milestone Pharmaceuticals is 366715 which is 123.3% above its average volume of 164225.

Moving Average

Milestone Pharmaceuticals’s value is below its 50-day moving average of $3.61 and way under its 200-day moving average of $5.60.

More news about Milestone Pharmaceuticals.

Losers Today

1. Medigus Ltd. (MDGSW) – -43%

NASDAQ ended the session with Medigus Ltd. sliding 43% to $0.03 on Friday, after five sequential sessions in a row of losses. NASDAQ jumped 0.31% to $11,823.96, after four consecutive sessions in a row of gains, on what was a somewhat up trend trading session today.

More news about Medigus Ltd..

2. Malacca Straits Acquisition Company Limited (MLACW) – -41%

NASDAQ ended the session with Malacca Straits Acquisition Company Limited dropping 41% to $0.04 on Friday, after five sequential sessions in a row of losses. NASDAQ rose 0.31% to $11,823.96, after four sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Yearly Top and Bottom Value

Malacca Straits Acquisition Company Limited’s stock is valued at $0.04 at 17:32 EST, under its 52-week low of $0.04.

More news about Malacca Straits Acquisition Company Limited.

3. Meten EdtechX Education Group Ltd. (METXW) – -22.65%

NASDAQ ended the session with Meten EdtechX Education Group Ltd. falling 22.65% to $0.04 on Friday while NASDAQ jumped 0.31% to $11,823.96.

More news about Meten EdtechX Education Group Ltd..

4. Marker Therapeutics (MRKR) – -21.67%

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

NASDAQ ended the session with Marker Therapeutics sliding 21.67% to $0.94 on Friday while NASDAQ rose 0.31% to $11,823.96.

Earnings Per Share

As for profitability, Marker Therapeutics has a trailing twelve months EPS of $-2.21.

Yearly Top and Bottom Value

Marker Therapeutics’s stock is valued at $0.94 at 17:32 EST, way below its 52-week high of $6.60 and above its 52-week low of $0.88.

Volume

Today’s last reported volume for Marker Therapeutics is 347229 which is 571.05% above its average volume of 51744.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 33.3% and 27.3%, respectively.

More news about Marker Therapeutics.

5. Aspen Group (ASPU) – -9.5%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group dropping 9.5% to $0.12 on Friday, after two consecutive sessions in a row of gains. NASDAQ rose 0.31% to $11,823.96, after four successive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.383.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.28%.

More news about Aspen Group.

6. Riot Blockchain (RIOT) – -8.45%

Riot Platforms, Inc., together with its subsidiaries, focuses on bitcoin mining operations in North America. It operates through Bitcoin Mining, Data Center Hosting, and Electrical Products and Engineering segments. As of December 31, 2021, it operated approximately 30,907 miners. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is headquartered in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain falling 8.45% to $8.67 on Friday, after two consecutive sessions in a row of gains. NASDAQ jumped 0.31% to $11,823.96, after four consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-0.3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36.07%.

Volume

Today’s last reported volume for Riot Blockchain is 25296600 which is 50.17% above its average volume of 16845100.

Revenue Growth

Year-on-year quarterly revenue growth declined by 28.6%, now sitting on 289.91M for the twelve trailing months.

Yearly Top and Bottom Value

Riot Blockchain’s stock is valued at $8.67 at 17:32 EST, way below its 52-week high of $23.66 and way above its 52-week low of $3.25.

Sales Growth

Riot Blockchain’s sales growth is negative 39.1% for the ongoing quarter and negative 10.4% for the next.

More news about Riot Blockchain.

7. Moleculin Biotech (MBRX) – -8.44%

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of topical treatment of cutaneous T-cell lymphoma. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and antimetabolites, targeting glycolysis and glycosylation. The company has partnerships and collaboration agreement with MD Anderson, DERMIN Sp. z o. o., Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

NASDAQ ended the session with Moleculin Biotech falling 8.44% to $0.94 on Friday while NASDAQ rose 0.31% to $11,823.96.

Earnings Per Share

As for profitability, Moleculin Biotech has a trailing twelve months EPS of $-1.763.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -35.91%.

Yearly Top and Bottom Value

Moleculin Biotech’s stock is valued at $0.94 at 17:32 EST, way under its 52-week high of $2.05 and way above its 52-week low of $0.82.

More news about Moleculin Biotech.

8. Xenetic Biosciences (XBIO) – -8.23%

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

NASDAQ ended the session with Xenetic Biosciences falling 8.23% to $0.39 on Friday, after five consecutive sessions in a row of losses. NASDAQ rose 0.31% to $11,823.96, after four successive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-1.704.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.85%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 18.6%, now sitting on 1.55M for the twelve trailing months.

Volatility

Xenetic Biosciences’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.45%, a negative 3.15%, and a positive 5.24%.

Xenetic Biosciences’s highest amplitude of average volatility was 2.45% (last week), 5.31% (last month), and 5.24% (last quarter).

Moving Average

Xenetic Biosciences’s value is way below its 50-day moving average of $0.50 and way under its 200-day moving average of $0.60.

More news about Xenetic Biosciences.

9. Marathon (MARA) – -7.8%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines cryptocurrencies with a focus on the blockchain ecosystem and the generation of digital assets in United States. As of December 31, 2021, it had approximately 8,115 bitcoins, which included the 4,794 bitcoins held in the investment fund. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Las Vegas, Nevada.

NASDAQ ended the session with Marathon sliding 7.8% to $7.80 on Friday, following the last session’s upward trend. NASDAQ jumped 0.31% to $11,823.96, after four consecutive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-0.13.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -41.77%.

More news about Marathon.

10. NuCana plc (NCNA) – -6.99%

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

NASDAQ ended the session with NuCana plc dropping 6.99% to $1.33 on Friday, following the last session’s upward trend. NASDAQ rose 0.31% to $11,823.96, after four successive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, NuCana plc has a trailing twelve months EPS of $-0.83.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -46.82%.

Moving Average

NuCana plc’s value is below its 50-day moving average of $1.46 and way above its 200-day moving average of $1.21.

Yearly Top and Bottom Value

NuCana plc’s stock is valued at $1.33 at 17:32 EST, way below its 52-week high of $2.24 and way higher than its 52-week low of $0.52.

More news about NuCana plc.

Stay up to date with our winners and losers daily report